Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: Studies with cyclosporine

American Journal of Clinical Nutrition

Volumn 87, Issue 4, 2008, Pages 863-871

  Paine, Mary F ^a   Widmer, Wilbur W ^c   Pusek, Susan N ^a   Beavers, Kimberly L ^b   Criss, Anne B ^a   Snyder, Jennifer ^b   Watkins, Paul B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c U S DEPARTMENT OF AGRICULTURE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FUROCOUMARIN DERIVATIVE; GLYCOPROTEIN P INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GRAPEFRUIT JUICE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN;

CITRUS X PARADISI;

EID: 42249088111     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/87.4.863     Document Type: Article

References (47)

1. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:101-10.
2. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003;33:10-6.
3. Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005;28:677-94.
4. Paine MF, Oberlies NH. Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 2007;3:67-80.
5. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
6. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-62.
7. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
8. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997;7:391-6.
9. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-33.
10. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998;11:252-9.
11. Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000;28:766-71.
12. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000;378:356-63.
13. Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 2004;32:1146-53.
14. Mohri K, Uesawa Y. Effects of furanocoumarin derivatives in grapefruit juice on nifedipine pharmacokinetics in rats. Pharm Res 2001;18:177-82.
15. Sahi J, Reyner EL, Bauman JN, Gueneva-Boucheva K, Burleigh JE, Thomas VH. The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. Drug Metab Dispos 2002;30:135-40.
16. Paine MF, Widmer WW, Hart HL, et al. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 2006;83:1097-105.
17. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
18. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.
19. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995;345:955-6.
20. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91.
21. Min DI, Ku YM, Perry PJ, et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996;62:123-5.
22. Ku YM, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol 1998;38:959-65.
23. Hermann M, Asberg A, Reubsaet JL, Sather S, Berg KJ, Christensen H. Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients. Int J Clin Pharmacol Ther 2002;40:451-6.
24. Dantzig AH, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities J Pharmacol Exp Ther 1999;290:854-62.
25. Mouly SJ, Paine MF, Watkins PB. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther 2004;308:941-8.
26. 3. Mol Pharmacol 1997;51:741-54.
27. Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 2005;312:1151-60.
28. Shaw PE. Use of a simple solvent optimization program to improve separation of limonin in citrus juices. J Chromatogr Sci 1986;24:364-6.
29. Widmer WW, Haun C. Analysis of limonin and flavonoids in citrus juices and byproduct extracts by direct injection and in-line samples clean-up. In: Berhow MA, Hasegawa S, Manners GD, eds. Citrus limonoids, functional chemicals in agriculture and food. Washington, DC: American Chemical Society, 2000:60-72.
30. Widmer W. One tangerine/grapefruit hybrid (tangelo) contains trace amounts of furanocoumarins at a level too low to be associated with grapefruit/drug interactions. J Food Sci 2005;70:C419-22.
31. Ooghe WC, Ooghe SJ, Detavernier CM, Huyghebaert A. Characterization of orange juice (Citrus sinensis) by polymethoxylated flavones. J Agric Food Chem 1992;42:2191-5.
32. Sendra JM, Navarro JL, Izquierdo L. C-18 solid-phase isolation and high-performance liquid-chromatography ultraviolet diode-array determination of fully methoxylated flavones in citrus juices. J Chromatogr Sci 1988;26:443-8.
33. Ohnishi A, Matsuo H, Yamada S, et al. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br J Pharmacol 2000;130:1369-77.
34. Takanaga H, Ohnishi A, Yamada S, et al. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther 2000;293:230-6.
35. Mertens-Talcott SU, De Castro WV, Manthey JA, Derendorf H, Butterweck V. Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells. J Agric Food Chem 2007;55:2563-8.
36. Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur J Clin Nutr 2004;58:1-9.
37. Bistrup C, Nielsen FT, Jeppesen UE, Dieperink H. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol Dial Transplant 2001;16:373-7.
38. Honda Y, Ushigome F, Koyabu N, et al. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 2004;143:856-64.
39. de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice-drug interactions: grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 2007;96:2808-17.
40. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′- Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999;65:237-44.
41. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.
42. Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005;33:518-23.
43. Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007;81:495-502.
44. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69:14-23.
45. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004;36(suppl):378S-91S.
46. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 2005;78:605-18.
47. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998;45:355-9.